Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
-
- STATUS
- Recruiting
-
- days left to enroll
- 81
-
- participants needed
- 150
-
- sponsor
- Duke University
Summary
This is a pilot study to determine the safety and efficacy of low dose aspirin for the prevention of venous thromboembolic events among women with advanced ovarian cancer receiving neoadjuvant chemotherapy.
Subjects who are receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer will be recruited from the Duke Gynecology Oncology clinic at Duke Cancer Institute. After discussion of the risks and benefits, written informed consent will be obtained for initiation of prophylactic, daily low dose aspirin (81 mg) therapy. Subjects will receive aspirin tablets in medication vials obtained from the Duke pharmacy supply and will be instructed to take one tablet daily until the day of their interval debulking surgery. Subjects will be followed throughout the primary treatment course and monitored for the occurrence of venous thromboembolic events. Subjects will also be instructed to complete medication adherence diaries that will be reviewed by the research team. The investigators hypothesize that daily low dose aspirin will reduce the incidence of venous thromboembolic events during neoadjuvant chemotherapy when compared to a historical control.
The incidence of venous thromboembolism among the study cohort will be calculated with an estimated 95% exact binomial confidence interval. A drop of greater than 20% (from 8% estimated in the historical control to 6.4%) in rate of venous thromboembolism would be considered clinically meaningful. The investigators will also monitor for adverse drug events related to low dose aspirin use, including major or minor bleeding events, clinically significant thrombocytopenia (resulting in treatment delay), and gastrointestinal complications. Of note, low dose aspirin for venous thromboembolism prevention is already considered an acceptable option for standard of care for patients with multiple myeloma receiving antiangiogenesis agents with chemotherapy and/or dexamethasone as well as for postoperative prophylaxis following some orthopedic procedures. The investigators therefore feel the potential benefit outweighs any clinically significant risks.
Details
| Condition | Ovarian disorder, Venous Thromboembolism, Ovarian Cancer, Thromboembolism, Ovarian Function, Recurrent Ovarian Cancer, ovarian carcinomas, cancer, ovarian, cancer ovarian, cancer of the ovary, ovarian tumors |
|---|---|
| Treatment | Aspirin |
| Clinical Study Identifier | NCT04352439 |
| Sponsor | Duke University |
| Last Modified on | 25 January 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer